Maersk seals deal on shipping COVID-19 vaccine in 2021
Maersk has sealed a deal to ship over one billion doses of COVAXX synthetic peptide-based vaccine globally to fight COVID-19 by the end of 2021.
COVAXX, a United States (U.S.) firm developing a multi-tope UB-612 vaccine using high precision, synthetic peptide platform to activate both B-cell and T-cell arm, aimed to bring COVID-19 vaccine to emerging and developing nations after regulatory authorities’ approval.
It is currently conducting Phase One clinical trials of its vaccine in Taiwan and had reached an agreement with the University of Nebraska Medical Centre to conduct Phase Two trials in the U.S., upon regulatory approval.
The company has advanced pre-commitments to manufacture 100 million doses of its vaccine during early 2021, and a billion doses by the end of 2021.
In September, COVAXX announced a deal with Dasa in Brazil to conduct large-scale human efficiency clinical trial in South America’s largest country.
Chief Executive Officer of COVAXX, Mei Mei Hu, said the vaccine was designed to mimic natural biology as preclinical studies have shown high immunogenicity and levels of neutralising titers against SARS-CoV-2.